Sort
4,870 grants matching “glp 1”
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,136,490David S Perlin · Hackensack University Medical Center · R01 · FY2020 · AI
RNAi Therapy for Spinocerebellar Ataxia Type 1
$1,135,776Beverly L Davidson · Children'S Hosp Of Philadelphia · UH2 · FY2016 · NS
RBD recombinant protein-based SARS vaccine for biodefense
$1,134,359Peter J Hotez · Baylor College Of Medicine · R01 · FY2014 · AI
A novel vaccine against multidrug-resistant gonorrhea
$1,133,414Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · AI
Universal room temperature stable influenza nanovaccine
$1,132,987Balaji Narasimhan · Iowa State University · R01 · FY2020 · AI
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
$1,132,870Jerzy Szewczyk · Biokier, Inc. · R44 · FY2017 · DK
Preclinical drug development in pancreatic cancer
$1,131,974Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception
$1,130,880Keiichiro Kushiro · Mucommune, Llc · R44 · FY2025 · HD
Potentiating an Anthrax DNA Vaccine with Electroporation
$1,128,919Ichor Medical Systems, Inc. · R42 · FY2004 · AI
Predicting Weight Regain Following Weight Loss Using Physiological Measures of Appetite and Energy Expenditure
$1,127,578Michael R Lowe · Drexel University · UH3 · FY2025 · DK
Predicting Weight Regain Following Weight Loss Using Physiological Measures of Appetite and Energy Expenditure
$1,127,574Michael R Lowe · Drexel University · UH3 · FY2025 · DK
Predicting Weight Regain Following Weight Loss Using Physiological Measures of Appetite and Energy Expenditure
$1,127,436Michael R Lowe · Drexel University · UH3 · FY2024 · DK
Development of a DIVI platform for issue resolution in pre-clinical drug development.
$1,126,395Brian Robert Wamhoff · Hemoshear Therapeutics, Llc · R44 · FY2015 · GM
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,125,966David S Perlin · Hackensack University Medical Center · R01 · FY2021 · AI
Predicting Weight Regain Following Weight Loss Using Physiological Measures of Appetite and Energy Expenditure
$1,125,377Michael R Lowe · Drexel University · UH3 · FY2023 · DK
A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study
$1,124,972James G. Moe · Oligomerix, Inc · R44 · FY2022 · AG
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens
$1,124,408Terry L Bowlin · Microbiotix, Inc · U01 · FY2010 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses
$1,122,164John H Eldridge · Profectus Biosciences, Inc. · R01 · FY2013 · AI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,121,874Jeffrey S Glenn · Stanford University · R01 · FY2019 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses
$1,120,171John H Eldridge · Profectus Biosciences, Inc. · R01 · FY2012 · AI
Assessment of a Digitally Controlled Aerosolized Nicotine Replacement Therapy
$1,118,284James M Davis · Predictably Human, Inc. · R42 · FY2025 · DA
SmartInsulin ADME and IND-enabling Preclinical Studies
$1,116,164Todd C Zion · Smartcells, Inc. · R44 · FY2008 · DK
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,114,898Zachary David Aron · Microbiotix, Inc · R01 · FY2018 · AI
Predicting Weight Regain Following Weight Loss Using Physiological Measures of Appetite and Energy Expenditure
$1,113,029Michael R Lowe · Drexel University · UH3 · FY2022 · DK
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,112,974Jeffrey S Glenn · Stanford University · R01 · FY2020 · AI